tildrakizumab
Almirall’s paediatric registration of Ebglyss for atopic dermatitis gets EMA acceptance
Atopic dermatitis affects a significant number of children and adolescents and often peaks in childhood
LEO Pharma to acquire Replay gene therapy platform
The acquisition will advance innovation for patients with rare skin diseases
J&J’s Icotyde approved by US FDA for plaque psoriasis
Plaque psoriasis affects over 125 million people worldwide
Almirall celebrates new offices in China to advance innovation in dermatology
The company’s R&D and commercial expertise represent valuable capabilities for future Chinese partners
Takeda’s zasocitinib demonstrates positive results in plaque psoriasis
Around 64 million people worldwide live with psoriasis
Global Healthy Living Foundation and Medscape Education Join Forces to Bridge the Gap Between Patients and Providers with Immunology Education
UPPER NYACK, N.Y.--(BUSINESS WIRE)--The Global Healthy Living Foundation (GHLF) today announced a new partnership with Medscape Education to advance patient-centered innovation within the Immunology Learning Nexus (Nexus), Medscape’s flagship multi-year...
Johnson & Johnson seeks first EMA approval for icotrokinra for plaque psoriasis
Icotrokinra is a first-in-class, once-daily tablet for moderate-to-severe plaque psoriasis
Almirall and Absci expand AI dermatological drug discovery partnership
The alliance has already led to the delivery of functional antibody leads against a difficult-to-drug target
Apogee Therapeutics’ atopic dermatitis candidate shows promise in phase 2 study
The inflammatory skin condition affects over 26 million people in the US
Honoring the Legacy of Dr. Robert Sidbury, MD, MPH
We are deeply saddened by the recent passing of Dr. Robert Sidbury. Dr. Sidbury was a visionary in pediatric dermatology whose dedication to advancing patient care inspired clinicians, researchers, and...
LEO Pharma gains access to Boehringer’s skin disease drug for €90m upfront
Spevigo is already approved in over 40 countries to treat generalised pustular psoriasis
Dermaliq and DEBRA partner to advance epidermolysis bullosa drug delivery
Approximately 500,000 people worldwide are affected by the rare genetic skin disorders